A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Completed · Phase 2

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

Study GIPF-002 is a phase 2 study designed to characterize the biologic and clinical effects of IFN-g 1b. The objective of the Study is to characterize the biologic and clinical effects of IFN-g 1b administered to patients with idiopathic pulmonary fibrosis (IPF). The Study will be conducted at multiple sites and enroll 30 patients with IPF who have failed treatment with corticosteroids.

Key facts

Study ID

NCT00047658

Run by

InterMune

People needed

32

Starts

2001-11-01

Expected to finish

2003-05-01

Last updated by the study team

2007-11-06

Who can join

Age: 20 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA, Dept. of Medicine — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.